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The cardiorenal syndrome
blockers has meant that more patients survive into the later stages of 
the disease. The clinical challenge ironically then retrogresses to one 
that involves optimal fl uid balance while preserving renal function. What 
we may not realise is that the underlying pathophysiology of this 
“terminal phase” of CHF is poorly understood. The management 
thereof can be an emotionally and cognitively demanding saga and 
ultimately there is no consensus amongst the “experts” as to its 
appropriate care. The cardiorenal syndrome in CHF results from 
major aberrations in the mutually benefi cial interaction between heart 
and kidney. It can be seen as a complex interaction between the heart, 
kidney and vasculature.
DEFINITION
The cardiorenal syndrome is defi ned as “worsening renal function that 
limits diuresis despite obvious clinical volume overload.”  This syndrome 
limits effective CHF therapy, prolongs hospitalization and has signifi cant 
prognostic implications. It predicts an increased rate of death and 
rehospitalization. The clinical picture of CHF relates to congested organs 
and hypoperfused tissues, exemplifi ed by the cardiorenal syndrome.
The defi nition of worsening renal function remains controversial, with 
suggestions including a 26.5 umol/l increase in serum creatinine (SCr) 
above baseline, a rise in SCr above a threshold (221umol/l), a percentage 
increase from baseline (>25%), or a combination of these factors.(1,2) 
Whatever the defi nition, clinically this syndrome is not diffi cult to 
recognise – the challenge is to fi nd effective therapies and management 
strategies. Seventy percent of patients admitted for acute deteriorating 
heart failure have decreased renal function and 20-45% will experience 
an increase in SCr in excess of 26.5 umol/l while in hospital.(3) Glomerular 
fi ltration rate (GFR) measures the fi ltration capacity of the kidneys and 
is considered the best overall index of renal function. GFR is usually 
estimated by creatinine-based equations that incorporate demographic 
characteristics, such as age, gender, race and weight to account for 
differences in muscle mass and hence creatinine generation. The 
formulae that we use to estimate GFR have their problems(4) and 
require cautious interpretation in daily practice. The variance is wide, at 
approximately 30 ml/min per 1.73 m2. The Cockroft-Gault formula 
developed in males with steady state creatinine and fi rst described 
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  The progress made in the medical and 
device therapy of chronic heart failure (CHF) due to left 
ventricular systolic dysfunction has heralded new problems. 
Patients present having survived longer with CHF, but with 
minimal exercise reserve and renal dysfunction with or 
without systemic congestion. We now recognise this 
clinical presentation as the cardiorenal syndrome. The 
classic hemodynamic/neurohormonal understanding of the 
syndrome explains only partly the pathophysiology, and it is 
now recognised that the kidney early on in a heart failure 
patient shows abnormal handling of a sodium load and 
changes in renal blood fl ow. Renal dysfunction is commonly 
seen in patients with CHF and the higher the level of 
the admission serum creatinine as well as an increase in 
serum creatinine during hospitalisation portends a graver 
prognosis. Chronic kidney disease itself is associated with a 
greater incidence of heart failure, but unravelling the 
pathophysiological mechanisms involved in this reciprocal 
relationship between the heart and the kidneys remains 
elusive. Essentially the problem remains in trying to 
maintain optimal fl uid balance while preserving renal 





Most doctors who treat patients suffering from chronic heart failure 
(CHF) caused by left ventricular systolic dysfunction recognise the “wet 
or dry”, cold patient presenting with minimal reserve on effort and 
renal dysfunction with or without hyponatremia. Our “success” in 
treating CHF with angiotensin converting enzyme inhibitors and beta-
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in 1976(5) with an arbitrary correction for females tends to overestimate 
GFR in the lower ranges. It is recommended that it not be used for 
prognostic purposes. The Modifi cation of Diet in Renal Disease (MDRD) 
equation developed predominantly in males with chronic kidney disease 
without diabetes mellitus is an improvement, but underestimates GFR 
in healthy people. However, it is more precise, especially in the lower 
ranges of GFR and was felt to be the most reliable in clinical practice.(4) 
This formula includes an adjustment for black individuals, allowing for 
their increased muscle mass.(6) Both these formulae can be used very 
well for pharmacokinetic purposes. Interestingly, serum creatinine 
measurements can vary between laboratories. We may therefore still 
require newer markers of GFR with cystatin C being used as a future 
good measurement of renal function.(7) 
There are 5 classes in the classifi cation of the cardiorenal syndrome 
(Table 1), but this article will concentrate on Class II, although this can 
be diffi cult to differentiate from Class IV.
THE HEART AND THE KIDNEY
The heart and the kidney are closely linked as regards physiological 
health. The heart is required to pump blood at a rate commensurate 
with the requirements of the metabolising tissues. The greatest 
responsibility for solute and water excretion is borne by the kidney. 
With normal functioning kidneys, approximately 180 litres of fl uid is 
fi ltered per day, yet only 2 litres are usually excreted. This underlines the 
great deal of work that the kidney performs, yet it only receives 19% of 
the cardiac output at rest and 3% with strenuous exercise. An increase 
in plasma volume is usually associated with increased sodium and water 
excretion by the kidneys. Paradoxically, in CHF sodium and water are 
retained despite an increase in plasma volume.(8) 
CLASSIC UNDERSTANDING
The classic understanding of the heart-kidney interaction in heart 
failure is based on an amalgamation of the hemodynamic and neuro-
hormonal approaches to understanding the syndrome.(8) Left ventricular 
systolic dysfunction results in decreased cardiac output, which sets up 
the activation of the renin-angiotensin-aldosterone system (RAAS), the 
sympathetic nervous and the natriuretic peptide systems. Via diminished 
renal blood fl ow and perfusion, structural renal changes occur that 
impair renal function and, together with neuro-hormonal activation, 
causes increased water and sodium retention, vasoconstriction and 
diminished cardiac performance. These adaptive mechanisms fail to 
normalise cardiac output including the cost of an increased circulating 
plasma volume, which then further amplifi es the downward spiral of 
heart failure begetting heart failure. Diuretic resistance ensues and the 
cardiorenal syndrome is “born”.
EARLY SIGNS OF CARDIO-RENAL INTERACTION
Deranged sodium handling
The classic concepts of the cardiorenal syndrome may be dissolving. 
Volpe et al.(9) described the effects of increased sodium intake on GFR, 
renal plasma fl ow and renal vascular resistance in mild asymptomatic 
HF. In both normal and mild heart failure subjects, the increased sodium 
intake (250 mmol/day vs. 100 mmol/day) caused GFR and renal plasma 
fl ow and fi ltered load of sodium to increase signifi cantly and renal 
vascular resistance to drop but, while the fractional clearance of water, 
excretion of potassium and sodium increased in normal subjects, it was 
signifi cantly reduced in the mild CHF group. These CHF patients had no 
clinical signs or symptoms of congestion. This inability to excrete a 
volume load precedes any evidence of reduced cardiac output. 
Importantly, after the addition of low doses of enalapril these effects 
were reversed and “normalised” the response of the mild CHF group 
to an increased sodium load. Despite normal hemodynamics and 
increased fi ltered sodium, less sodium was excreted, implying that 
abnormal sodium retention is seen early in CHF, relating to an 
abnormality of proximal tubular sodium handling (distal delivery of 
sodium is decreased in CHF) which is undetectable during normal 
sodium intake. Enalapril increases the distal delivery of sodium.
Altered glomerular hemodynamics
A test of renal hemodynamic reserve (the angiotensin II / nitric oxide 
balance) involves the assessment of the glomerular vasodilatory 
response to an amino acid infusion. In another interesting study, Magri 
et al.(10) infused amino acid into normal and mild asymptomatic CHF 
patients. Normally, an amino acid infusion will reduce renal vascular 
Class I Acute cardiac disease affecting renal function
Class II Chronic cardiac disease causing renal disease
Class III Acute renal disease affecting cardiac function
Class IV Chronic renal disease causing cardiac disease
Class V Secondary cardiorenal syndrome (CRS)
TABLE 1: Classifi cation of the cardiorenal syndrome
resistance and increase GFR. GFR, effective renal plasma fl ow increased 
and renal vascular resistance decreased in the normal subjects but not 
the CHF group. Only after 6 weeks of enalapril (5mg) or losartan (50 
mg) administration at 20h00 (without affecting basal systemic or renal 
hemodynamics) was the “normal response” elicited in the CHF group. 
The early loss of renal functional reserve in CHF appears to relate in 
part anyway, to local angiotensin II production and the intricate balance 
between angiotensin II and nitric oxide. This led the investigators to 
conclude that reduced ejection fraction is a poor predictor of cardiac 
output and renal blood fl ow and that aberrations in the intra-renal 
renin-angiotensin-aldosterone axis are present early, before the so-
called classic theory of hemodynamic compromise plays a role. 
Further detracting from the classic theory is the work of Stevenson and 
Tillisch.(11) In a short-term hemodynamic study in CHF and performed 
in the resting state, they showed that stroke volume is often maximal 
and can be maintained after reducing LV fi lling pressures to normal 
while keeping systemic vascular resistance stable. During exercise, more 
volume reserve may be required. This tends to underline too, the 
different hemodynamics present in acute heart failure vs. CHF. In acute 
heart failure, fi lling pressures need to be maximised to maintain stroke 
volume, but in the chronically dilated heart LV fi lling pressures and 
ventricular volumes cannot be equated. High ventricular volumes can 
be maintained with normal fi lling pressures.
PREVALENCE
Large HF interventional trials (SOLVD Prevention (SOLVD-P),(12) 
SOLVD Treatment (SOLVD-T))(13) have shown that the blood urea/
creatinine ratio (indicating a pre-renal component to the renal 
dysfunction) is slightly, but signifi cantly lower in those with moderate 
renal insuffi ciency than those without. In the Treatment trial, no 
signifi cant difference in this ratio was seen in those with and without 
renal insuffi ciency.(1) Interestingly 21% of 3 673 patients in the 
SOLVD-P trial had a GFR < 60 ml/min. This fi gure is all the more 
remarkable, as the patients in this trial were NYHA FC I –II.  In the 
SOLVD-T trial, 35% of 2 161 patients had a GFR < 60 ml/min and 
these were majority Class II patients.(14) In “real life” renal dysfunction 
may be more common as this category of patient is often excluded 
from trials. Overall a serum Creatinine > 132 umol/l and a GFR 
< 60ml/min is seen in approximately 50% of CHF patients.
All this tends to underline the fact that renal dysfunction occurs early 
in CHF before hemodynamic insults, patients often have preceding 
decline in GFR before presenting in clinical CHF, implying shared risk 
factors for 2 independent conditions, but as CHF worsens so does the 
degree of renal dysfunction. General arteriosclerosis is highly correlated 
with severity of glomerulosclerosis and of renal arteriosclerosis, 
probably explaining the difference in prevalence of renal dysfunction 
amongst different population groups.(6) As a contrast to predominantly 
“western” patients, in a retrospective analysis of 163 Black African 
patients with predominantly NYHA FC II/III CHF, only 12% had an 
eGFR < 60ml/min.(6) This prevalence is considerably lower than that 
reported in the SOLVD trials. The average age of the South African 
cohort was younger (48yrs) and concomitant atherosclerotic disease 
was in all likelihood low, although this was not formally assessed in 
the analysis. As seen in the recently published CORONA study,(15) 
the mean entry SCr was 115 umol/l with 24% of entrants having 
SCr > 130 umol/l. The mean estimated GFR was < 60 ml/min indicating 
that the majority of patients in CORONA would be classifi ed as having 
Stage 3 chronic kidney disease. This is despite the mean entry blood 
pressure being 129/76 and 37% of entrants being NYHA FC II. As has 
been previously noted,(12) depressed renal function does not appear to 
be characterized by a low-output state as a signifi cant number of these 
patients present with elevated blood pressure. Not only is there an 
association of 2 independent conditions, but a calculated creatinine 
clearance of < 60 ml / min is independently associated with all cause 
death, pump failure death and heart failure hospitalizations.
Chronic kidney disease can be seen as catalyst to the development of 
CHF(16) and CHF itself is also an important aggravating factor for further 
renal dysfunction by various mechanisms, not all currently understood. 
According to the NHANES data, 28% of patients with renal dysfunction 
have CHF. What is clear, however, is that the classical hemodynamic 
theory is inadequate to explain (especially in the early phase) the entire 
cardiorenal syndrome. What appears more pertinent is that LV systolic 
dysfunction is associated early on with renal dysregulation that is not 
related to altered hemodynamics primarily, but rather to intra-renal 
AII/NO imbalance. Adequacy of baseline renal function is an important 
determinant involved in the progression to the cardiorenal syndrome 
and the maintenance of good renal function delays progression from LV 
systolic dysfunction to frank CHF. Once CHF is established, then 
hemodynamic, infl ammatory, and oxidative stressors all play a role 





Pathophysiological mechanisms underlying this reciprocal relationship 
between the heart and kidneys are still enigmatic.(18) Renal failure 
increases cardiovascular mortality in HF patients by up to 1% per each 
1ml/min decrease in creatinine clearance.(3) Although renal dysfunction 
predicts all-cause mortality, it is most predictive of death from 
progressive heart failure. In the ADHERE registry,(19) patients presenting 
with reduced LV systolic function CHF and SCr < 176umol/l had an 
in-hospital mortality of 2.9%, but those presenting with SCr > 176 
umol/l had an 8.4% mortality. Not only was baseline SCr predictive of 
mortality, but an increase during hospitalization further worsened 
prognosis. Autoregulation of renal perfusion is effective down to a 
systolic BP of 90 mmHg and/or a cardiac index of 1.5. The decline in 
renal function however is often worse when hypotension is associated 
with venous congestion as the renal fi ltration gradient is further 
reduced.
We have made great strides in the pharmacological management of 
chronic HF over the last 3 decades. Importantly, however, although we 
prolong survival with drugs, eventually the patient deteriorates(20) and 
we are increasingly presented with a very ill patient, hypoperfused, 
dyspnoeic and with signifi cant and progressive renal dysfunction. 
As more patients survive into advanced stages of disease, it is increasingly 
diffi cult to maintain optimal fl uid balance while preserving renal function. 
In the CORONA trial, despite 92% of patients being on an ACEI or 
ARB, 75% on a beta-blocker and 40% on an aldosterone antagonist, a 
third of all patients (from both arms of the trial) were dead by two and 
a half years. 
CONCLUSION
The phenomenon of a cardiorenal limit to standard heart failure 
medications is becoming more obvious as the experience with HF 
lengthens. Much research needs to be done to further understand the 
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